Compare — Georgia Financials

panel 2026-09-21Ask

Pooled trend

5 companies

Aggregate by year

GEL, thousands · money Σ · ratios from summed bases · growth on the pooled series

Metric	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024
Revenue	23,422	29,476	36,815	38,026	45,185	42,284	44,993
EBITDA	2,897	5,642	1,916	5,576	8,435	3,226	4,922
Net profit	2,753	4,894	1,736	4,937	6,106	2,172	3,687
Total assets	28,381	32,949	33,515	39,813	42,359	46,624	51,307
n (companies reporting)	4	4	4	5	5	5	5

Per-company contribution by year

XLSX

GEL, thousands

Company	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024
Neoparmi	11,787	13,399	16,583	16,848	18,458	15,356	19,189
Bioparmi	7,068	6,619	10,847	12,858	12,412	9,686	10,150
Biopolusi	4,234	7,022	7,406	5,460	10,596	12,756	6,488
Inovas	333	2,435	1,978	2,861	1,997	1,891	5,010
Krokus Pharma	—	—	—	0	1,722	2,595	4,156

Rows are the raw pool — every peer, including any excluded from the sums above, so the de-duplication stays auditable. Tinted cells are the excluded company-years.

Peer coverage varies by year — FY2018–FY2021 pool fewer than the 5 picked companies (see the n row). A year is never dropped because one peer is missing.

Pooled figures sum every peer in the set. Known parent/subsidiary groups that file separately are de-duplicated; groups not yet curated may still be counted more than once.